CrossRef Text and Data Mining
Result of CrossRef Text and Data Mining Search is the related articles with entitled article. If you click link1 or link2 you will be able to reach the full text site of selected articles; however, some links do not show the full text immediately at now. If you click CrossRef Text and Data Mining Download icon, you will be able to get whole list of articles from literature included in CrossRef Text and Data Mining.
The Role of Glucagon-Like Peptide 1 Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors in Reducing Cardiovascular Events in Patients with Type 2 Diabetes
Gwang Sil Kim, Joong Hyun Park, Jong Chul Won
Endocrinol Metab. 2019;34(2):106-116.   Published online May 9, 2019
DOI: https://doi.org/10.3803/EnM.2019.34.2.106

Excel Download

The Role of Glucagon-Like Peptide 1 Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors in Reducing Cardiovascular Events in Patients with Type 2 Diabetes
Endocrinology and Metabolism. 2019;34(2):106   Crossref logo
Link1 Link2 Link3

Combining Glucagon-Like Peptide 1 Receptor Agonists and Sodium–Glucose Cotransporter 2 Inhibitors to Target Multiple Organ Defects in Type 2 Diabetes
Diabetes Spectrum. 2020;33(2):165-174   Crossref logo
Link1 Link2

Mechanisms by Which Glucagon-Like-Peptide-1 Receptor Agonists and Sodium-Glucose Cotransporter-2 Inhibitors Reduce Cardiovascular Risk in Adults With Type 2 Diabetes Mellitus
Canadian Journal of Diabetes. 2020;44(1):93-102   Crossref logo
Link1 Link2

Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials
BMJ. 2022;o109   Crossref logo
Link1 Link2

Evidence‐based comparison of glucagon‐like peptide receptor agonists and sodium–glucose cotransporter 2 inhibitors
Journal of Diabetes Investigation. 2019;11(1):17-19   Crossref logo
Link1 Link2 Link3

Erratum to: Glucagon-like Peptide-1 Receptor Agonists versus Sodium-Glucose Cotransporter Inhibitors for Treatment of T2DM
Journal of the Endocrine Society. 2021;5(3):   Crossref logo
Link1 Link2

CORRIGENDUM FOR “Glucagon-like Peptide-1 Receptor Agonists versus Sodium-Glucose Cotransporter Inhibitors for Treatment of T2DM”
Journal of the Endocrine Society. 2020;4(12):   Crossref logo
Link1 Link2

PDB68 DEMOGRAPHIC AND CLINICAL PROFILES OF PATIENTS WITH TYPE 2 DIABETES NEWLY INITIATING SODIUM-GLUCOSE COTRANSPORTER-2 INHIBITORS COMPARED TO GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS
Value in Health. 2019;22:S152   Crossref logo
Link1 Link2

The new type 2 diabetes mellitus therapy: comparison between the two classes of drugs GLPR (glucagon-like peptide receptor) agonists and SGLT2 (sodium–glucose cotransporter 2) inhibitors
European Heart Journal Supplements. 2020;22(Supplement_L):L28-L32   Crossref logo
Link1 Link2

Comparing medication persistence among patients with type 2 diabetes using sodium-glucose cotransporter 2 inhibitors or glucagon-like peptide-1 receptor agonists in real-world setting
Diabetes Research and Clinical Practice. 2021;180:109035   Crossref logo
Link1 Link2